Covered recipient · General Payments record
AZIZ ISMAIL SHAIBANI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$156.84
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $156.84 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $134.55 | 1 |
| Octapharma USA, Inc. | $22.29 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AZIZ ISMAIL SHAIBANI
NPI 1164423588 · CMS profile ID 1108296
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1164423588?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164423588?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164423588?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- AZIZ ISMAIL SHAIBANI, NPI 1164423588, CMS profile ID 1108296, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1164423588?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $156.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $134.55 | 09/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908085923 | CMS |
| Octapharma USA, Inc. | $22.29 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937557651 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,532,027.97 | 451 |
| PY2024 | Principal investigator | $1,574,518.05 | 897 |
| PY2023 | Principal investigator | $948,026.50 | 160 |
| PY2022 | Principal investigator | $516,060.09 | 29 |
| PY2021 | Principal investigator | $553,923.14 | 58 |
| PY2020 | Principal investigator | $220,943.95 | 29 |
| PY2019 | Principal investigator | $182,148.36 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
451 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $680.00 | 12/31/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228724166 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,203.41 | 12/26/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184280338 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,758.80 | 12/26/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184280340 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,088.66 | 12/26/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184280342 |
| Principal investigator 1 | PFIZER INC. | $8,538.60 | 12/25/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228734557 |
| Principal investigator 1 | ARGENX US, INC. | $1,365.00 | 12/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150960 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,120.00 | 12/19/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613539 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $856.65 | 12/19/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613552 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $4,572.00 | 12/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613508 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,497.00 | 12/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613513 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $193.00 | 12/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613535 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $921.00 | 12/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613547 |
| Principal investigator 1 | ARGENX US, INC. | $585.00 | 12/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150909 |
| Principal investigator 1 | ARGENX US, INC. | $2,145.00 | 12/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150945 |
| Principal investigator 1 | ARGENX US, INC. | $1,755.00 | 12/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150949 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 12/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150952 |
| Principal investigator 1 | ARGENX US, INC. | $3,382.00 | 12/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150964 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 12/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151125 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,793.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613505 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,061.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613518 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $4,572.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613522 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $4,572.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613526 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $193.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613530 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $921.00 | 12/01/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 11/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184266479 |
| Principal investigator 1 | PFIZER INC. | $3,091.20 | 11/26/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228729658 |
| Principal investigator 1 | ARGENX US, INC. | $1,755.00 | 11/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150937 |
| Principal investigator 1 | ARGENX US, INC. | $2,757.40 | 11/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150941 |
| Principal investigator 1 | ARGENX US, INC. | $2,275.00 | 11/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150972 |
| Principal investigator 1 | ARGENX US, INC. | $2,315.40 | 11/20/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150933 |
| Principal investigator 1 | ARGENX US, INC. | $7,222.45 | 11/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150929 |
| Principal investigator 1 | ARGENX US, INC. | $5,326.95 | 11/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150968 |
| Principal investigator 1 | ARGENX US, INC. | $1,170.00 | 11/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150987 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $326,181.07 | 11/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase | No dispute reported | 06/30/2026 | 1190302535 |
| Principal investigator 1 | PFIZER INC. | $2,937.20 | 11/04/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228727527 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 11/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151133 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,120.26 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255791 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,987.78 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255793 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,235.02 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255797 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,088.66 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255799 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,758.80 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255801 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,120.26 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,235.02 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 10/30/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184255809 |
| Principal investigator 1 | ARGENX US, INC. | $1,170.00 | 10/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150976 |
| Principal investigator 1 | PFIZER INC. | $1,358.00 | 10/28/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228741959 |
| Principal investigator 1 | ARGENX US, INC. | $1,745.90 | 10/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150921 |
| Principal investigator 1 | ARGENX US, INC. | $2,702.15 | 10/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150925 |
| Principal investigator 1 | ARGENX US, INC. | $3,491.80 | 10/16/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150905 |
| Principal investigator 1 | ARGENX US, INC. | $975.00 | 10/16/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150917 |
| Principal investigator 1 | ARGENX US, INC. | $585.00 | 10/16/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150956 |
| Principal investigator 1 | ARGENX US, INC. | $5,404.30 | 10/16/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150983 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250147 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250151 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250153 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250155 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250181 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250183 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250185 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250187 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250189 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250193 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250195 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250197 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250199 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250209 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250215 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250217 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250219 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250221 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250225 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250227 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250229 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250231 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250235 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 10/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184250237 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,166.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613465 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $5,383.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613470 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $193.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613474 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $193.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613478 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,279.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613483 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $210.50 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613488 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $283.10 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613491 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,454.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613496 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $4,397.00 | 10/10/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613499 |
| Principal investigator 1 | ARGENX US, INC. | $2,591.65 | 10/09/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150897 |
| Principal investigator 1 | ARGENX US, INC. | $2,569.55 | 10/09/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150901 |
| Principal investigator 1 | PFIZER INC. | $8,488.20 | 10/08/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228740286 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 10/03/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150913 |
| Principal investigator 1 | ARGENX US, INC. | $1,365.00 | 10/03/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150979 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 10/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151129 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,101.90 | 09/24/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067671 |
| Principal investigator 1 | ARGENX US, INC. | $2,757.40 | 09/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151085 |
| Principal investigator 1 | ARGENX US, INC. | $585.00 | 09/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151012 |
| Principal investigator 1 | ARGENX US, INC. | $5,514.80 | 09/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151065 |
| Principal investigator 1 | ARGENX US, INC. | $1,170.00 | 09/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151077 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 09/12/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151054 |
| Principal investigator 1 | ARGENX US, INC. | $2,665.00 | 09/12/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151074 |
| Principal investigator 1 | ARGENX US, INC. | $852.00 | 09/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150996 |
| Principal investigator 1 | ARGENX US, INC. | $5,409.40 | 09/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151008 |
| Principal investigator 1 | ARGENX US, INC. | $1,365.00 | 09/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151028 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $195.48 | 09/04/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $33,720.72 | 09/04/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182003 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,500.00 | 09/03/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613454 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $273.60 | 09/03/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613457 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $10,000.00 | 09/03/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613460 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $280.00 | 09/03/2025 | Non-covered Recipient Entity Houston Neurocare PA | hase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) | No dispute reported | 06/30/2026 | 1211613463 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 09/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151144 |
| Principal investigator 1 | ARGENX US, INC. | $5,139.10 | 08/26/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151046 |
| Principal investigator 1 | ARGENX US, INC. | $1,170.00 | 08/21/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151036 |
| Principal investigator 1 | ARGENX US, INC. | $2,839.85 | 08/14/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151032 |
| Principal investigator 1 | ARGENX US, INC. | $1,901.45 | 08/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151016 |
| Principal investigator 1 | ARGENX US, INC. | $2,569.55 | 08/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,521.50 | 08/06/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184224514 |
| Principal investigator 1 | PFIZER INC. | $3,511.20 | 08/02/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228765653 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 08/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151140 |
| Principal investigator 1 | ARGENX US, INC. | $5,713.70 | 07/31/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151024 |
| Principal investigator 1 | Amgen Inc. | $374.85 | 07/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TX | P3 Inebilizumab in Adults w/MG (MINT) | No dispute reported | 06/30/2026 | 1246645024 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,203.41 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220566 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220568 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,203.41 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,758.80 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220572 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,987.78 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220574 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,235.02 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220576 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220578 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220580 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 07/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184220582 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $46,657.20 | 07/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1185549031 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 07/22/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151004 |
| Principal investigator 1 | ARGENX US, INC. | $4,044.00 | 07/22/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151050 |
| Principal investigator 1 | ARGENX US, INC. | $975.00 | 07/17/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151000 |
| Principal investigator 1 | ARGENX US, INC. | $2,425.90 | 07/17/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151041 |
| Principal investigator 1 | ARGENX US, INC. | $8,128.55 | 07/17/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151058 |
| Principal investigator 1 | PFIZER INC. | $3,990.00 | 07/11/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228785861 |
| Principal investigator 1 | ARGENX US, INC. | $1,745.90 | 07/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151062 |
| Principal investigator 1 | ARGENX US, INC. | $1,475.00 | 07/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150992 |
| Principal investigator 1 | ARGENX US, INC. | $8,272.20 | 07/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151069 |
| Principal investigator 1 | ARGENX US, INC. | $5,701.50 | 07/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151081 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 07/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151136 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $10,275.62 | 06/30/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | No dispute reported | 06/30/2026 | 1249093493 |
| Principal investigator 1 | PFIZER INC. | $6,709.80 | 06/26/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228724976 |
| Principal investigator 1 | ARGENX US, INC. | $1,755.00 | 06/24/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150875 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,879.20 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211 | No dispute reported | 06/30/2026 | 1248066699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210098 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210104 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210106 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210110 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210116 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210118 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210120 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210124 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210136 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210138 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210140 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210142 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210180 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210406 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210408 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210412 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210418 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 06/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184210426 |
| Principal investigator 1 | ARGENX US, INC. | $1,745.90 | 06/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150835 |
| Principal investigator 1 | ARGENX US, INC. | $2,600.00 | 06/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150879 |
| Principal investigator 1 | ARGENX US, INC. | $5,559.00 | 06/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150882 |
| Principal investigator 1 | ARGENX US, INC. | $5,625.30 | 06/12/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150847 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,954.80 | 06/11/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125874 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,954.80 | 06/11/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143657 |
| Principal investigator 1 | ARGENX US, INC. | $2,672.00 | 06/05/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150829 |
| Principal investigator 1 | ARGENX US, INC. | $2,569.55 | 06/05/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150851 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 06/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,088.66 | 05/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184200201 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,206.33 | 05/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184200203 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 05/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184200205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,445.63 | 05/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184200207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 05/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184200209 |
| Principal investigator 1 | ARGENX US, INC. | $13,333.95 | 05/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150825 |
| Principal investigator 1 | ARGENX US, INC. | $2,895.10 | 05/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150832 |
| Principal investigator 1 | ARGENX US, INC. | $3,777.00 | 05/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150856 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192124696 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125856 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130854 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130879 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130890 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133038 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133138 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133152 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133170 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133182 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143669 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182011 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182025 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182029 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182033 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192183531 |
| Principal investigator 1 | ARGENX US, INC. | $2,340.00 | 05/22/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150821 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/20/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130885 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 05/20/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144235 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 05/20/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182021 |
| Principal investigator 1 | ARGENX US, INC. | $10,963.30 | 05/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150893 |
| Principal investigator 1 | PFIZER INC. | $3,490.20 | 05/14/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228772161 |
| Principal investigator 1 | ARGENX US, INC. | $2,412.00 | 05/02/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150867 |
| Principal investigator 1 | ARGENX US, INC. | $104.00 | 05/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151108 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 05/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151117 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $242.90 | 04/30/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | No dispute reported | 06/30/2026 | 1249093381 |
| Principal investigator 1 | ARGENX US, INC. | $8,283.25 | 04/28/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150862 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 04/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125909 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 04/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130861 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $50.00 | 04/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143650 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $256.50 | 04/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144244 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 04/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144249 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,140.83 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,656.68 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,445.63 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,206.33 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,805.90 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,120.26 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,088.66 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,002.60 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,552.25 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,088.66 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,552.25 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,110.65 | 04/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184189925 |
| Principal investigator 1 | PFIZER INC. | $8,811.60 | 04/24/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228778705 |
| Principal investigator 1 | ARGENX US, INC. | $27,341.95 | 04/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150840 |
| Principal investigator 1 | ARGENX US, INC. | $1,560.00 | 04/23/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150871 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184810 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184812 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184814 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184816 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $405.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184846 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184852 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184854 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184856 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184860 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184862 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184864 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184866 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184870 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184874 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184876 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184878 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184893 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184899 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184903 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184913 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184935 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184941 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184959 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184965 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184967 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184969 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184971 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184975 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $201.15 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184981 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.75 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184983 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184985 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184987 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $202.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $405.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $337.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184184999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $67.50 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/18/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184185017 |
| Principal investigator 1 | ARGENX US, INC. | $1,950.00 | 04/15/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150818 |
| Principal investigator 1 | Amgen Inc. | $23,375.00 | 04/14/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | P3 Inebilizumab in Adults w/MG (MINT) | No dispute reported | 06/30/2026 | 1246645020 |
| Principal investigator 1 | ARGENX US, INC. | $5,679.70 | 04/08/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150843 |
| Principal investigator 1 | ARGENX US, INC. | $390.00 | 04/08/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150887 |
| Principal investigator 1 | ARGENX US, INC. | $2,839.85 | 04/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150814 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 04/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151112 |
| Principal investigator 1 | ARGENX US, INC. | $2,967.35 | 03/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150787 |
| Principal investigator 1 | ARGENX US, INC. | $2,895.10 | 03/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150796 |
| Principal investigator 1 | ARGENX US, INC. | $6,166.75 | 03/19/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150809 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $8,692.50 | 03/17/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | No dispute reported | 06/30/2026 | 1249093293 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $20,289.00 | 03/14/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067257 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $6,003.00 | 03/14/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067259 |
| Principal investigator 1 | ARGENX US, INC. | $8,725.25 | 03/11/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150761 |
| Principal investigator 1 | ARGENX US, INC. | $2,535.00 | 03/11/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150771 |
| Principal investigator 1 | ARGENX US, INC. | $2,895.10 | 03/11/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150805 |
| Principal investigator 1 | ARGENX US, INC. | $6,904.00 | 03/06/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150800 |
| Principal investigator 1 | ARGENX US, INC. | $2,569.55 | 03/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150781 |
| Principal investigator 1 | ARGENX US, INC. | $8,847.00 | 03/04/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150792 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 03/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151105 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192124691 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $486.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125863 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125880 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133032 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133058 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133080 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143653 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $607.50 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143666 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 02/27/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182008 |
| Principal investigator 1 | PFIZER INC. | $2,979.25 | 02/26/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228720145 |
| Principal investigator 1 | ARGENX US, INC. | $5,765.60 | 02/25/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150764 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 02/11/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150758 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,644.05 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,758.80 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,987.78 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152884 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,805.85 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152886 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,618.19 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152888 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,552.25 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,805.85 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152892 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,552.25 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,552.25 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152896 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,140.83 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152898 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,656.68 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152900 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,758.80 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152902 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,987.78 | 02/10/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis | No dispute reported | 06/30/2026 | 1184152904 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,759.32 | 02/06/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144258 |
| Principal investigator 1 | ARGENX US, INC. | $8,570.55 | 02/05/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150751 |
| Principal investigator 1 | PFIZER INC. | $10,052.00 | 02/05/2025 | Non-covered Recipient Entity Houston Neurocare PA | A PHASE 3 MULTICENTER OPENLABEL EXTENSION STUDY TO INVESTIGATE THE LONGTERM SAFETY TOLERABILITY AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS | No dispute reported | 06/30/2026 | 1228753902 |
| Principal investigator 1 | ARGENX US, INC. | $104.00 | 02/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151089 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 02/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151101 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $370,401.94 | 01/31/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS) | No dispute reported | 06/30/2026 | 1190302537 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $5,000.00 | 01/30/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | No dispute reported | 06/30/2026 | 1249093163 |
| Principal investigator 1 | PTC Therapeutics, Inc. | $2,173.50 | 01/30/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC857IN ADULT SUBJECTS WITHAMYOTROPHIC LATERAL SCLEROSIS(CARDINALS) | No dispute reported | 06/30/2026 | 1249093165 |
| Principal investigator 1 | ARGENX US, INC. | $2,856.85 | 01/29/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150777 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $249.75 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130867 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $249.75 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130896 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $411.75 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133025 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133066 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $729.00 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133073 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $729.00 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133130 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133146 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133159 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133164 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133176 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143661 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143674 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 01/28/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144254 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $9,160.20 | 01/22/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067813 |
| Principal investigator 1 | ARGENX US, INC. | $14,300.40 | 01/17/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150745 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $5,327.00 | 01/17/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067811 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,644.20 | 01/14/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067809 |
| Principal investigator 1 | ARGENX US, INC. | $8,685.30 | 01/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150754 |
| Principal investigator 1 | ARGENX US, INC. | $11,339.90 | 01/07/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237150768 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125885 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125891 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125896 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192125902 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192130873 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133045 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $121.50 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192133052 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192143678 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144240 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192144265 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192182016 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $128.25 | 01/07/2025 | Non-covered Recipient Entity NERVE AND MUSCLE CENTER OF TEXAS | A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STU | No dispute reported | 06/30/2026 | 1192183528 |
| Principal investigator 1 | ARGENX US, INC. | $70.00 | 01/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151093 |
| Principal investigator 1 | ARGENX US, INC. | $104.00 | 01/01/2025 | Non-covered Recipient Entity HOUSTON NEUROCARE PA | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | No dispute reported | 06/30/2026 | 1237151097 |